Reduced-dose JAK inhibitor initiation: comparable retention, unless prognostic factors stack up

Design

Multicentre registry cohort with propensity score matching

Population

1,135 Japanese patients with RA starting a JAK inhibitor, 2013 to 2025

Primary outcome

24-month drug retention

Effect

Comparable retention reduced vs standard dose with preserved renal function

This Japanese multicentre registry study, published in April, included 1,135 patients with rheumatoid arthritis starting a JAK inhibitor between 2013 and 2025. The main analysis was in patients with preserved renal function, where a reduced starting dose reflects clinical choice rather than necessity, using propensity matching.

Twenty-four-month drug retention was similar with reduced and standard doses, disease activity improved similarly, and glucocorticoid use stayed low in both. In patients with three or four poor prognostic factors, standard dosing was associated with better persistence; in those with few, reduced dosing performed comparably. In reduced renal function, standard dosing was associated with higher retention.

Retention is an indirect outcome, and the stratified findings were flagged by the authors as needing caution.

The study is relevant where cost and safety concerns push clinicians towards lower doses, as they often do in India. It supports considering a reduced dose in lower-risk patients, but not in those with multiple poor prognostic factors.

• Consider a reduced JAK inhibitor starting dose in patients with few poor prognostic factors and normal renal function.
• Prefer standard dosing when three or more poor prognostic factors are present.
• Follow licensed dose adjustments for renal impairment.
• Reassess disease activity at 3 months whichever dose is chosen.

Why it matters

Lower doses cut cost and may reduce harm, but only if they work as well in the patients chosen for them.

Don't overread it

This is observational registry data; the subgroup and renal findings need confirmation.

The statistics, in plain English

Drug retention reflects both effectiveness and tolerability, so similar retention does not prove identical efficacy. Propensity matching reduces but cannot remove confounding by why clinicians chose a lower dose.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.